The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?
Identifieur interne : 000E47 ( PubMed/Curation ); précédent : 000E46; suivant : 000E48The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?
Auteurs : T R Lopez Penha [Pays-Bas] ; L M Van Roozendaal [Pays-Bas] ; M L Smidt [Pays-Bas] ; L J Boersma [Pays-Bas] ; M F Von Meyenfeldt [Pays-Bas] ; A C Voogd [Pays-Bas] ; E M Heuts [Pays-Bas]Source :
- Breast (Edinburgh, Scotland) [ 1532-3080 ] ; 2015.
Descripteurs français
- KwdFr :
- Aisselle, Biopsie de noeud lymphatique sentinelle, Bras, Facteurs de risque, Femelle, Humains, Lymphadénectomie (effets indésirables), Lymphoedème (), Lymphoedème (diagnostic), Lymphoedème (étiologie), Métastase lymphatique, Stade de la tumeur (tendances), Tumeurs du sein (anatomopathologie), Épaule.
- MESH :
- anatomopathologie : Tumeurs du sein.
- diagnostic : Lymphoedème.
- effets indésirables : Lymphadénectomie.
- tendances : Stade de la tumeur.
- étiologie : Lymphoedème.
- Aisselle, Biopsie de noeud lymphatique sentinelle, Bras, Facteurs de risque, Femelle, Humains, Lymphoedème, Métastase lymphatique, Épaule.
English descriptors
- KwdEn :
- MESH :
- adverse effects : Lymph Node Excision.
- diagnosis : Lymphedema.
- etiology : Lymphedema.
- pathology : Breast Neoplasms.
- surgery : Lymphedema.
- trends : Neoplasm Staging.
- Arm, Axilla, Female, Humans, Lymphatic Metastasis, Risk Factors, Sentinel Lymph Node Biopsy, Shoulder.
Abstract
Primary aim is to give an overview of changes in axillary staging and treatment of breast cancer patients. Secondly, we aim to identify patients with a high arm/shoulder morbidity risk, and describe a strategy to improve early detection and treatment. Recent and initiated studies on axillary staging and treatment were evaluated and clustered for clinically node negative and clinically node positive breast cancer patients, together with studies on pathology, detection and (surgical) prevention and treatment of lymphedema. For clinically node negative patients, the indication for axillary lymph node dissection in sentinel node positive patients is fading. On the contrary, clinically node positive patients are routinely subjected to an axillary lymph node dissection, in combination with other therapies associated with an increased lymphedema risk, such as mastectomy, adjuvant radiation- and (taxane-based) chemotherapy. Techniques for prevention, early detection and (surgical) treatment of lymphedema are being developed. Axillary staging and treatment in breast cancer patients with a clinically node negative status will become less invasive, thereby reducing the incidence of morbidity. Nevertheless, in patients with a clinically node positive status, aggressive treatment will still be required for oncologic control. For these patients, a surveillance program should be implemented in order to apply (curative) surgical treatment for lymphedema.
DOI: 10.1016/j.breast.2015.04.008
PubMed: 26051795
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E47
Links to Exploration step
pubmed:26051795Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?</title><author><name sortKey="Lopez Penha, T R" sort="Lopez Penha, T R" uniqKey="Lopez Penha T" first="T R" last="Lopez Penha">T R Lopez Penha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Plastic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Plastic Surgery, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Van Roozendaal, L M" sort="Van Roozendaal, L M" uniqKey="Van Roozendaal L" first="L M" last="Van Roozendaal">L M Van Roozendaal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: lorivanroozendaal@gmail.com.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Smidt, M L" sort="Smidt, M L" uniqKey="Smidt M" first="M L" last="Smidt">M L Smidt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Boersma, L J" sort="Boersma, L J" uniqKey="Boersma L" first="L J" last="Boersma">L J Boersma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Maastricht University Medical Center (MAASTRO Clinic), Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Radiation Oncology, Maastricht University Medical Center (MAASTRO Clinic), Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Von Meyenfeldt, M F" sort="Von Meyenfeldt, M F" uniqKey="Von Meyenfeldt M" first="M F" last="Von Meyenfeldt">M F Von Meyenfeldt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Voogd, A C" sort="Voogd, A C" uniqKey="Voogd A" first="A C" last="Voogd">A C Voogd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Epidemiology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Heuts, E M" sort="Heuts, E M" uniqKey="Heuts E" first="E M" last="Heuts">E M Heuts</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26051795</idno><idno type="pmid">26051795</idno><idno type="doi">10.1016/j.breast.2015.04.008</idno><idno type="wicri:Area/PubMed/Corpus">000E47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E47</idno><idno type="wicri:Area/PubMed/Curation">000E47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?</title><author><name sortKey="Lopez Penha, T R" sort="Lopez Penha, T R" uniqKey="Lopez Penha T" first="T R" last="Lopez Penha">T R Lopez Penha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Plastic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Plastic Surgery, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Van Roozendaal, L M" sort="Van Roozendaal, L M" uniqKey="Van Roozendaal L" first="L M" last="Van Roozendaal">L M Van Roozendaal</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: lorivanroozendaal@gmail.com.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Smidt, M L" sort="Smidt, M L" uniqKey="Smidt M" first="M L" last="Smidt">M L Smidt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Boersma, L J" sort="Boersma, L J" uniqKey="Boersma L" first="L J" last="Boersma">L J Boersma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Maastricht University Medical Center (MAASTRO Clinic), Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Radiation Oncology, Maastricht University Medical Center (MAASTRO Clinic), Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Von Meyenfeldt, M F" sort="Von Meyenfeldt, M F" uniqKey="Von Meyenfeldt M" first="M F" last="Von Meyenfeldt">M F Von Meyenfeldt</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Voogd, A C" sort="Voogd, A C" uniqKey="Voogd A" first="A C" last="Voogd">A C Voogd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Epidemiology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author><author><name sortKey="Heuts, E M" sort="Heuts, E M" uniqKey="Heuts E" first="E M" last="Heuts">E M Heuts</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht</wicri:regionArea></affiliation></author></analytic><series><title level="j">Breast (Edinburgh, Scotland)</title><idno type="eISSN">1532-3080</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Arm</term><term>Axilla</term><term>Breast Neoplasms (pathology)</term><term>Female</term><term>Humans</term><term>Lymph Node Excision (adverse effects)</term><term>Lymphatic Metastasis</term><term>Lymphedema (diagnosis)</term><term>Lymphedema (etiology)</term><term>Lymphedema (surgery)</term><term>Neoplasm Staging (trends)</term><term>Risk Factors</term><term>Sentinel Lymph Node Biopsy</term><term>Shoulder</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aisselle</term><term>Biopsie de noeud lymphatique sentinelle</term><term>Bras</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie (effets indésirables)</term><term>Lymphoedème ()</term><term>Lymphoedème (diagnostic)</term><term>Lymphoedème (étiologie)</term><term>Métastase lymphatique</term><term>Stade de la tumeur (tendances)</term><term>Tumeurs du sein (anatomopathologie)</term><term>Épaule</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lymphadénectomie</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Stade de la tumeur</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Neoplasm Staging</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Arm</term><term>Axilla</term><term>Female</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Risk Factors</term><term>Sentinel Lymph Node Biopsy</term><term>Shoulder</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Aisselle</term><term>Biopsie de noeud lymphatique sentinelle</term><term>Bras</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lymphoedème</term><term>Métastase lymphatique</term><term>Épaule</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Primary aim is to give an overview of changes in axillary staging and treatment of breast cancer patients. Secondly, we aim to identify patients with a high arm/shoulder morbidity risk, and describe a strategy to improve early detection and treatment. Recent and initiated studies on axillary staging and treatment were evaluated and clustered for clinically node negative and clinically node positive breast cancer patients, together with studies on pathology, detection and (surgical) prevention and treatment of lymphedema. For clinically node negative patients, the indication for axillary lymph node dissection in sentinel node positive patients is fading. On the contrary, clinically node positive patients are routinely subjected to an axillary lymph node dissection, in combination with other therapies associated with an increased lymphedema risk, such as mastectomy, adjuvant radiation- and (taxane-based) chemotherapy. Techniques for prevention, early detection and (surgical) treatment of lymphedema are being developed. Axillary staging and treatment in breast cancer patients with a clinically node negative status will become less invasive, thereby reducing the incidence of morbidity. Nevertheless, in patients with a clinically node positive status, aggressive treatment will still be required for oncologic control. For these patients, a surveillance program should be implemented in order to apply (curative) surgical treatment for lymphedema.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26051795</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>05</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3080</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Breast (Edinburgh, Scotland)</Title><ISOAbbreviation>Breast</ISOAbbreviation></Journal><ArticleTitle>The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?</ArticleTitle><Pagination><MedlinePgn>543-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2015.04.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0960-9776(15)00102-2</ELocationID><Abstract><AbstractText>Primary aim is to give an overview of changes in axillary staging and treatment of breast cancer patients. Secondly, we aim to identify patients with a high arm/shoulder morbidity risk, and describe a strategy to improve early detection and treatment. Recent and initiated studies on axillary staging and treatment were evaluated and clustered for clinically node negative and clinically node positive breast cancer patients, together with studies on pathology, detection and (surgical) prevention and treatment of lymphedema. For clinically node negative patients, the indication for axillary lymph node dissection in sentinel node positive patients is fading. On the contrary, clinically node positive patients are routinely subjected to an axillary lymph node dissection, in combination with other therapies associated with an increased lymphedema risk, such as mastectomy, adjuvant radiation- and (taxane-based) chemotherapy. Techniques for prevention, early detection and (surgical) treatment of lymphedema are being developed. Axillary staging and treatment in breast cancer patients with a clinically node negative status will become less invasive, thereby reducing the incidence of morbidity. Nevertheless, in patients with a clinically node positive status, aggressive treatment will still be required for oncologic control. For these patients, a surveillance program should be implemented in order to apply (curative) surgical treatment for lymphedema.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopez Penha</LastName><ForeName>T R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Plastic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Roozendaal</LastName><ForeName>L M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: lorivanroozendaal@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smidt</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boersma</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Maastricht University Medical Center (MAASTRO Clinic), Maastricht, The Netherlands; GROW - School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Meyenfeldt</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voogd</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuts</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast</MedlineTA><NlmUniqueID>9213011</NlmUniqueID><ISSNLinking>0960-9776</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="N">Sentinel Lymph Node Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012782" MajorTopicYN="N">Shoulder</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Axillary lymph node dissection</Keyword><Keyword MajorTopicYN="N">Breast neoplasms</Keyword><Keyword MajorTopicYN="N">Lymphedema</Keyword><Keyword MajorTopicYN="N">Morbidity</Keyword><Keyword MajorTopicYN="N">Radiation therapy</Keyword><Keyword MajorTopicYN="N">Sentinel lymph node biopsy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26051795</ArticleId><ArticleId IdType="pii">S0960-9776(15)00102-2</ArticleId><ArticleId IdType="doi">10.1016/j.breast.2015.04.008</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26051795
|texte= The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26051795" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |